Novartis Accelerates Drug Discovery Using AI Platforms to Shorten Development Timelines

Novartis announced that it is accelerating drug discovery timelines by integrating artificial intelligence platforms into its research pipeline, aiming to shorten the period from target identification to pre‑clinical testing and improve overall efficiency.

AI platforms employed by Novartis use machine learning models to screen large chemical libraries, prioritize candidates with favorable safety profiles, and predict biological activity, thereby reducing the need for extensive laboratory assays and cutting development costs.

Clinical candidates already moved forward under the AI‑driven workflow include several early‑stage therapies targeting oncology and rare diseases, with some slated to enter Phase I trials within the next twelve months.

Industry impact could be significant as Novartis expects its AI integration to set new benchmarks for speed and cost‑effectiveness in pharmaceutical development, prompting competitors to adopt similar technologies and potentially reshaping the drug pipeline landscape.